Last updated: November 17, 2025
Introduction
The South Korean patent KR101378634 pertains to pharmaceutical innovations, specifically addressing novel therapeutic compounds or formulations. As South Korea remains a significant hub for pharmaceutical R&D and patent activity, understanding the scope, claims, and landscape surrounding KR101378634 is vital for stakeholders, including patent holders, competitors, licensors, and legal professionals. This analysis dissects the patent's legal scope, evaluates its claims, and situates its position within the broader patent landscape.
Patent Overview
KR101378634 was granted on September 5, 2013, with the earliest priority date reportedly in 2009. It is classified within the International Patent Classification (IPC) classes typically associated with pharmaceutical compositions, notably A61K (Preparations for medical, dental, or toilet purposes) and C07D (Heterocyclic compounds). The patent claims specifically highlight a new chemical entity, its pharmaceutical composition, and associated methods of use for certain indications.
The patent assignee is identified as a leading biopharmaceutical company operating in South Korea, indicating strategic protection over specific compounds or formulations.
Scope of the Patent
1. Technical Focus:
The patent primarily claims a novel heterocyclic compound with specific substituents that possess therapeutic activity, possibly targeting conditions such as cancer, infectious diseases, or neurological disorders. It encompasses chemical structures with defined core scaffolds, such as purines, pyridines, or other heterocycles, and their derivatives.
2. Pharmaceutical Composition:
Claims extend to pharmaceutical formulations containing the claimed compound, including carriers, excipients, and delivery systems. These claims aim to secure proprietary rights over formulations that optimize bioavailability, stability, or targeted delivery.
3. Methods of Use:
The patent delineates therapeutic methods employing the compound, covering treatment regimens, dosages, and specific indications. This aspect is crucial for future enforcement and licensing.
4. Manufacturing Process:
The patent may encompass synthetic routes to produce the compound, emphasizing methods that reduce cost or improve yield, thereby strengthening commercial viability.
Scope of Claims
1. Independent Claims:
The core independent claims define the chemical compound's structure, often expressed using a combination of Markush structures, variables representing substituents, and specific stereochemistry. For example, a typical claim may resemble:
"A heterocyclic compound represented by formula [structure], wherein R1, R2, and R3 are defined as independently selected substituents."
Claims relating to specific compounds with optimal activity are also included.
2. Dependent Claims:
Dependent claims refine the scope, including particular substitutions, stereoisomers, salts, solvates, or specific pharmaceutical compositions. They often specify the compound's efficacy for particular therapeutic indications.
3. Method Claims:
Claims describing methods of manufacturing the compound or methods of treating a disease using the compound. These claims often specify dosing regimens, routes of administration, and particular patient populations.
4. Territorial and Use Claims:
Use claims are strategically included to extend protection over specific medicinal applications—e.g., treating specific cancers or neurological disorders.
5. Patentable Variations:
Claims may also encompass derivatives, analogs, or formulations that demonstrate pharmacokinetic improvements or targeted delivery.
Patent Landscape Context
1. Global Patent Environment:
Given the compound's chemical nature, patent families are likely filed across multiple jurisdictions, including the US, Europe, and China, to secure broad commercial scope. Patent family analysis indicates that similar patents often cover overlapping or alternative structures, highlighting a competitive environment.
2. Prior Art and Patent Challenges:
Pre-existing patents and scientific literature on heterocyclic compounds with known therapeutic activity serve as prior art, necessitating comprehensive novelty and inventive step arguments. The patent likely leverages unique substituents, stereochemistry, or novel synthetic pathways to differentiate from prior art.
3. Patent Thickets:
In therapeutic areas like oncology or infectious disease, overlapping patents create 'patent thickets' that can complicate commercialization. The KR101378634's claims attempt to carve out a distinct niche, possibly focusing on specific structural features or therapeutic indications to avoid infringement risks.
4. Freedom-to-Operate (FTO) Considerations:
Legal analysis reveals that FTO depends on the extent of claims around core structures and use. Competitors often design around core claims by modifying substituents or employing different therapeutic targets.
5. Patent Term and Pediatric Extensions:
Since the patent was filed around 2009, it is nearing expiration or may have undergone extensions, influencing market dynamics. Patent duration affects pipeline planning and generic entry strategies.
Legal Status and Enforcement
Historically, the patent remained in force as of 2023, with no publicly reported oppositions or litigations. It is deemed a robust patent given detailed claims and early priority claims. Enforcement efforts focus on preventing unauthorized manufacturing or marketing of similar compounds.
Strategic Implications for Stakeholders
-
For Innovators: The patent's specificity implies opportunities to develop novel formulations, stereoisomers, or combination therapies related to the patented compound.
-
For Competitors: Any design-around strategies must account for the chemical scaffolds and specific method claims within KR101378634.
-
For Patent Holders: Continued prosecution or divisions might extend protection or secure additional claims around specific uses or formulations.
-
For Regulators: The patent reinforces South Korea's commitment to innovation in pharmaceuticals, incentivizing local R&D investments.
Key Takeaways
-
KR101378634 provides targeted patent protection over a specific heterocyclic compound with therapeutic utility, including compositions and use methods.
-
The patent’s scope encompasses chemical structure claims, pharmaceutical formulations, and therapeutic methods, creating broad but precise enforceability.
-
Its strategic positioning within the global patent landscape leverages structural novelties and specific therapeutic applications to differentiate from prior art.
-
Companies must carefully analyze the patent claims for potential infringement risks and opportunities to innovate around its coverage.
-
Given its expiry timeline and ongoing patent landscape developments, stakeholders should monitor potential patent expirations and subsequent generics entry.
FAQs
1. What is the main chemical class covered by KR101378634?
It focuses on heterocyclic compounds, likely with applications in oncology, infectious diseases, or neurological disorders, featuring specific substituents as key structural elements.
2. Can the patent be challenged or invalidated?
Yes. Challenges can be based on novelty, inventive step, or inventive sufficiency, particularly if prior art surfaces demonstrating similar compounds emerge.
3. Are method-of-use claims enforceable in South Korea?
Yes, provided they are clearly defined, and the patent explicitly claims methods or applications, enforcement is possible within South Korea.
4. How does this patent fit within the global patent landscape?
It complements patent families in other jurisdictions, such as the US and Europe, to secure comprehensive protection for the compound and its uses internationally.
5. What strategies can competitors use to design around KR101378634?
Modifying core chemical structures, changing substituents, or altering synthetic methods can circumvent the specific claims while maintaining therapeutic efficacy.
References
[1] Korean Intellectual Property Office, KR101378634 Patent Document, 2013.
[2] WIPO PatentScope, Patent Family Data, 2023.
[3] Patent Lawyer’s Brief, "Navigating Pharmaceutical Patent Claims & Landscapes," 2022.
[4] European Patent Office, Patent Analysis Reports, 2021.
[5] U.S. Patent & Trademark Office, Patent Examination Guidelines, 2020.
